Literature DB >> 20461808

A case-control study of Parkinson's disease and tobacco use: gene-tobacco interactions.

Giuseppe De Palma1, Finlay D Dick, Stefano Calzetti, Neil W Scott, Gordon J Prescott, Aileen Osborne, Neva Haites, Paola Mozzoni, Anna Negrotti, Augusto Scaglioni, Antonio Mutti.   

Abstract

A case-control study of genetic, environmental, and occupational risk factors for Parkinson's disease (PD) was carried out in five European countries (Italy, Malta, Romania, Scotland, and Sweden) to explore the possible contribution of interactions among host and environmental factors in sporadic PD. Whereas smoking habits confirmed its negative association with PD, a possible modulatory role of genetic polymorphisms was investigated to obtain further mechanistic insights. We recruited 767 cases of PD and 1989 age-matched and gender-matched controls. Participants completed an interviewer-administered questionnaire including the history of smoking habits. The polymorphisms of genes involved either in metabolism of compounds contained in tobacco smoke (CYP2D6, CYP1B1, GSTM1, GSTT1, GSTM3, GSTP1, NQO1, SOD2, EPHX and NAT2) or in dopaminergic neurotransmission (MAOA, MAOB, DAT1 and DRD2) were characterized by PCR based methods on genomic DNA. We found evidence of statistically significant gene-tobacco interaction for GSTM1, NAT2, and GSTP1, the negative association between tobacco smoking and PD being significantly enhanced in subjects expressing GSTM1-1 activity, in NAT2 fast acetylators, and in those with the GSTP1*B*C haplotype. Owing to the retrospective design of the study, these results require confirmation. (c) 2010 Movement Disorder Society.

Entities:  

Mesh:

Year:  2010        PMID: 20461808     DOI: 10.1002/mds.22980

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

1.  Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study.

Authors:  Lisa F Potts; Alex C Cambon; Owen A Ross; Rosa Rademakers; Dennis W Dickson; Ryan J Uitti; Zbigniew K Wszolek; Shesh N Rai; Matthew J Farrer; David W Hein; Irene Litvan
Journal:  BMC Med Genet       Date:  2012-03-17       Impact factor: 2.103

2.  Comparative analysis of four disease prediction models of Parkinson's disease.

Authors:  Nadella Kumudini; Shaik Mohammad Naushad; Balraj Alex Stanley; Manoharan Niveditha; Gunasekaran Sharmila; Konda Kumaraswami; Rupam Borghain; Rukmini Mridula; Vijay Kumar Kutala
Journal:  Mol Cell Biochem       Date:  2015-10-05       Impact factor: 3.396

Review 3.  Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.

Authors:  Mohd Sami Ur Rasheed; Abhishek Kumar Mishra; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2017-09-04       Impact factor: 3.996

4.  Glutathione S-transferase T1 and M1 null genotypes and Parkinson's disease risk: evidence from an updated meta-analysis.

Authors:  Hongzhou Liu; Jie Peng; Jiajia Gao; Fang Zheng; Chaorong Tie
Journal:  Neurol Sci       Date:  2015-04-14       Impact factor: 3.307

5.  Environmental tobacco smoke and Parkinson's disease.

Authors:  Susan Searles Nielsen; Lisa G Gallagher; Jessica I Lundin; W T Longstreth; Terri Smith-Weller; Gary M Franklin; Phillip D Swanson; Harvey Checkoway
Journal:  Mov Disord       Date:  2011-11-16       Impact factor: 10.338

6.  SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies.

Authors:  Desheng Zhai; Songji Li; Ying Zhao; Zhicheng Lin
Journal:  Neurosci Lett       Date:  2013-11-07       Impact factor: 3.046

7.  Genetic modification of the association of paraquat and Parkinson's disease.

Authors:  Samuel M Goldman; Freya Kamel; G Webster Ross; Grace S Bhudhikanok; Jane A Hoppin; Monica Korell; Connie Marras; Cheryl Meng; David M Umbach; Meike Kasten; Anabel R Chade; Kathleen Comyns; Marie B Richards; Dale P Sandler; Aaron Blair; J William Langston; Caroline M Tanner
Journal:  Mov Disord       Date:  2012-10-08       Impact factor: 10.338

8.  No evidence of substantia nigra telomere shortening in Parkinson's disease.

Authors:  Gavin Hudson; David Faini; Andrea Stutt; Martin Eccles; Louise Robinson; David J Burn; Patrick F Chinnery
Journal:  Neurobiol Aging       Date:  2011-07-27       Impact factor: 4.673

9.  Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population.

Authors:  Chikako Kiyohara; Yoshihiro Miyake; Midori Koyanagi; Takahiro Fujimoto; Senji Shirasawa; Keiko Tanaka; Wakaba Fukushima; Satoshi Sasaki; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Hiroyuki Shimada; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  BMC Neurol       Date:  2011-07-25       Impact factor: 2.474

10.  Polymorphisms of GSTT1, GSTM1, and EPHX genotypes in patients with cryptogenic polyneuropathy: a case-control study.

Authors:  Jonas Lindh; Peter Söderkvist; Mats Fredrikson; Shahrzad Hosseininia; Martin Tondel; Bodil Persson; Magnus Vrethem
Journal:  Brain Behav       Date:  2011-11       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.